With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Related: Bristol Myers's stock pops as earnings top estimates and company raises guidance In September, Bristol Myers's shares rose after the FDA approved Cobenfy. The drug, previously called KarXT, ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.
Stocktwits on MSN7d
Bristol-Myers Hits 14-Month High After AbbVie’s Schizophrenia Drug Fails, Boosting Retail SentimentBristol Myers Squibb ($BMY) stock rocketed over 11% in early morning trading on Monday to hit a 14-month high of $61.08 after ...
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback